Methods for immunotherapy-based treatment and assessment of cancer
Disclosed herein are methods of treating or assessing cancer in a subject wherein it has been determined whether the cancer comprises a loss of function mutation or disruption in an immune pathway. The loss of function mutation or disruption can be in JAK1 or JAK2. The loss of function mutation or disruption can be in B2M. The methods can include administering an immune checkpoint therapy such as anti-PD1 or anti-PDL1. The methods can include administering an alternative therapy to an immune checkpoint therapy. In some aspects, the method includes determining whether the cancer comprises a loss of function mutation or disruption in an immune pathway.
1. A method of treating a subject having cancer, comprising:
a) administering to the subject an anti-PD-1 therapy, wherein the cancer has been determined to not comprise a loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2); or
b) administering to the subject a cancer therapy alternative to that in (a) wherein the cancer has been determined to comprise at least one loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2).
2. A method of assessing and treating a subject having cancer, comprising:
a) determining or having determined by sequencing whether the cancer comprises a loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2); and
b) determining or having determined from the results of (a) that the subject is a candidate for:
1) an anti-PD-1 therapy when the cancer is negative for a loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2); or
2) a cancer therapy alternative to that in (1) when the cancer is positive for at least one loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2); and
(c) administering the therapy of (b) to the subject based on the results of step (b).
3. The method of claim 2 , wherein the determining step comprises obtaining a dataset from a third party that has processed a sample from the cancer to experimentally determine mutation status, optionally wherein the third party is directed to process the sample from the cancer to produce the dataset.
4. The method of claim 2 , wherein the loss of function mutation in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2) is a mutation or disruption that truncates a Janus kinase 1 (JAK1) or a Janus kinase 2 (JAK2) protein, inactivates a JAK1 or a JAK2 protein, deletes a JAK1 or a JAK2 gene, or alters normal mRNA processing of a JAK1 or a JAK2 gene.
5. The method of claim 4 , wherein the mutation is JAK1 Q503*, JAK1 W690*, JAK1 D775N, JAK1 P429S, JAK1 F111L, JAK2 F547_splice, JAK2 D313_splice, JAK2 T555S, JAK2 N729I, JAK2 R761K, or JAK2 P1023S.
6. The method of claim 2 , wherein the loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2) has a mutation status selected from the group consisting of:
a) the loss of function mutation is homozygous;
b) the loss of function mutation is present at an allelic frequency different than that of a wild-type allele, optionally wherein no copies of the wild-type allele remain; and
c) the disruption is epigenetic silencing.
7. The method of claim 2 , wherein the method comprises determining or having determined from the results of (a) that the subject is a candidate for anti-PD-1 therapy, wherein the cancer has been determined to not comprise the loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2).
8. The method of claim 2 , wherein the method comprises determining or having determined from the results of (a) that the subject is a candidate for: the alternative cancer therapy of (2) wherein the cancer has been determined to comprise the at least one loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2) or the at least one loss of function mutation.
9. The method of claim 2 , wherein the cancer is
a PD-L1 positive (+) cancer.
10. The method of claim 2 , wherein the cancer is melanoma, skin cutaneous melanoma, non-small cell lung cancer, colon cancer, endometrial cancer, kidney cancer, bladder cancer, Merkel cell carcinoma, or Hodgkin lymphoma.
11. The method of claim 2 , wherein the anti-PD-1 therapy comprises an anti-PD-1 antibody, optionally wherein the antibody comprises nivolumab/BMS-936558/MDX-1106, pembrolizumab/MK-3475, pidilizumab/CT-011, or PDR001.
12. The method of claim 2 , wherein the alternative cancer therapy of (2)is selected from the group consisting of a mutant BRAF inhibitor, a MEK inhibitor, an ERK inhibitor, and any combination thereof.
13. The method of claim 2 , wherein the sequencing further comprises prior target amplification by PCR.
14. A method of assessing and treating a subject having cancer, comprising:
a) determining or having determined by sequencing whether the cancer comprises a loss of function mutation or disruption in Janus kinase 2 (JAK2);
b) determining or having determined from the results of (a) that the subject is a candidate for
an anti-PD-1 therapy when the cancer is negative for a loss of function mutation or disruption in Janus kinase 2 (JAK2);
and
(c) administering the therapy of (b) to the subject based on the results of step (b).
15. The method of claim 1 , wherein the cancer has been determined to not comprise the loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2) using a sequencing assay.
16. The method of claim 1 , wherein the cancer has been determined to comprise the at least one loss of function mutation or disruption in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2) using a sequencing assay.
17. The method of claim 2 , wherein the cancer is breast invasive carcinoma, prostate adenocarcinoma, lung adenocarcinoma, or colorectal adenocarcinoma.